IOVANCE BIOTHERAPEUTICS, INC. Cash and Restricted Cash
IOVANCE BIOTHERAPEUTICS, INC. (IOVA) had Cash and Restricted Cash of $116.77 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents · last filed 2026-08-06
- 2026-06-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $116.77M.
- 2026-03-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $202.50M.
- 2025-12-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $169.06M.
- 2025-09-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $164.10M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents |
|---|---|
| 2026-06-30 | $116.77M 10-Q · filed 2026-08-06 |
| 2026-03-31 | $202.50M 10-Q · filed 2026-05-07 |
| 2025-12-31 | $169.06M 10-Q · filed 2026-08-06 |
| 2025-09-30 | $164.10M 10-Q · filed 2025-11-06 |
| 2025-06-30 | $138.41M 10-Q · filed 2026-08-06 |
| 2025-03-31 | $178.05M 10-Q · filed 2026-05-07 |
| 2024-12-31 | $122.05M 10-Q · filed 2026-08-06 |
| 2024-09-30 | $170.54M 10-Q · filed 2025-11-06 |
| 2024-06-30 | $235.11M 10-Q · filed 2025-08-07 |
| 2024-03-31 | $140.62M 10-Q · filed 2025-05-08 |
| 2023-12-31 | $181.32M 10-K · filed 2026-02-24 |
| 2023-09-30 | $334.15M 10-Q · filed 2024-11-07 |
| 2023-06-30 | $296.44M 10-Q · filed 2024-08-08 |
| 2023-03-31 | $549.91M 10-Q · filed 2024-05-09 |
| 2022-12-31 | $238.16M 10-K · filed 2026-02-24 |
| 2022-09-30 | $124.80M 10-Q · filed 2023-11-07 |
| 2022-06-30 | $114.50M 10-Q · filed 2023-08-08 |
| 2022-03-31 | $98.44M 10-Q · filed 2023-05-10 |
| 2021-12-31 | $84.31M 10-K · filed 2025-02-27 |
| 2021-09-30 | $64.67M 10-Q · filed 2022-11-03 |
| 2021-06-30 | $88.85M 10-Q · filed 2022-08-04 |
| 2021-03-31 | $138.04M 10-Q · filed 2022-05-05 |
| 2020-12-31 | $72.85M 10-K · filed 2024-02-28 |
| 2020-09-30 | $73.83M 10-Q · filed 2021-11-04 |
| 2020-06-30 | $166.14M 10-Q · filed 2021-08-05 |
| 2020-03-31 | $58.06M 10-Q · filed 2021-05-06 |
| 2019-12-31 | $19.42M 10-K · filed 2023-02-28 |
| 2019-09-30 | $44.34M 10-Q · filed 2020-11-05 |
| 2019-06-30 | $82.36M 10-Q · filed 2020-08-06 |
| 2019-03-31 | $54.09M 10-Q · filed 2020-05-05 |
| 2018-12-31 | $82.15M 10-K · filed 2022-02-24 |
| 2018-09-30 | $80.74M 10-Q · filed 2019-11-04 |
| 2018-06-30 | $246.02M 10-Q · filed 2019-08-01 |
| 2017-12-31 | $145.37M 10-K · filed 2021-02-25 |
| 2016-12-31 | $106.72M 10-K · filed 2020-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 | |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Greenland Mines Ltd (GRML) | United States | $2.362B |